SCHEMBL4762946

SCHEMBL4762946

CCc1c(C(=O)O)ccnc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.50
KDM4E B2RXH2 6/20 0.49
ASPH Q12797 3/20 0.49
KDM8 Q8N371 3/20 0.49
KDM5B Q9UGL1 5/20 0.40
KDM5A P29375 4/20 0.40
SYK P43405 2/20 0.38
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRA4 P48169 2/20 0.38
GABRE P78334 2/20 0.38
GABRA6 Q16445 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30963968 0.84 KDM4E (0.39) NAPRTKDM4EASPHKDM8L3MBTL1
SCHEMBL19857473 0.80 KDM4E (0.55) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL15527710 0.80 GABRP (0.46) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL6931488 0.79 NOS2 (0.55) NAPRTKDM4EASPHKDM8KDM5B
SCHEMBL31402348 0.79 KDM5B (0.41) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL4954467 0.79 LMNA (0.50) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL28260878 0.76 KDM4E (0.39) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL14836840 0.76 GABRP (0.39) KDM4EASPHKDM8KDM5BKDM5A
SCHEMBL16837130 0.76 NAPRT (0.55) NAPRTKDM4EASPHKDM8KDM5B
SCHEMBL2027279 0.76 NAPRT (0.55) NAPRTKDM4EASPHKDM8KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312211-A1 Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
EP-1991545-A2 ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES AstraZeneca AB (SE) 2008-11-19 EP disclosed
WO-2007071965-A2 ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES ASTRAZENECA AB (SE) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312211-A1 Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 SDHA, QDPR, PNKP NAPRT 664/4885KDM4E 1269/4885ASPH 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.